Emerging Roles of Post-Translational Modifications in Skin Diseases: Current Knowledge, Challenges and Future Perspectives

References

• Chen J, Liu Q, Zeng L, Huang X. Protein acetylation/deacetylation: a potential strategy for fungal infection control. Front Microbiol. 2020;11:2505. doi:10.3389/fmicb.2020.574736
   Web of Science ®Google Scholar
• Hao L, Park J, Jang H-Y, Bae EJ, Park B-H. Inhibiting protein kinase activity of pyruvate kinase M2 by SIRT2 deacetylase attenuates psoriasis. J Investig Dermatol. 2021;141(2):355–363.e6. doi:10.1016/j.jid.2020.06.024
   PubMed Web of Science ®Google Scholar
• Giblin W, Bringman-Rodenbarger L, Guo AH, et al. The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. J Clin Invest. 2021;131(12):e138926. doi:10.1172/JCI138926
   PubMed Web of Science ®Google Scholar
• Fan X, Yan K, Meng Q, et al. Abnormal expression of SIRTs in psoriasis: decreased expression of SIRT 1-5 and increased expression of SIRT 6 and 7. Int J Mol Med. 2019;44(1):157–171. doi:10.3892/ijmm.2019.4173
   PubMed Web of Science ®Google Scholar
• Xu F, Xu J, Xiong X, Deng Y. Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep. 2019;24(1):70–74. doi:10.1080/13510002.2019.1658377
   PubMedGoogle Scholar
• Sestito R, Madonna S, Scarponi C, et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J. 2011;25(3):916–927. doi:10.1096/fj.10-172288
   PubMed Web of Science ®Google Scholar
• Xie S, Su Z, Zhang B, et al. SIRT1 activation ameliorates aldara-induced psoriasiform phenotype and histology in mice. J Invest Dermatol. 2015;135(7):1915–1918. doi:10.1038/jid.2015.82
   PubMed Web of Science ®Google Scholar
• Yu X, Li H, Zhu M, et al. Involvement of p53 acetylation in growth suppression of cutaneous T-cell lymphomas induced by HDAC Inhibition. J Investig Dermatol. 2020;140(10):2009–2022.e4. doi:10.1016/j.jid.2019.12.041
   PubMed Web of Science ®Google Scholar
• Rodriguez KM, Cohen MS. Chemical genetic methodologies for identifying protein substrates of PARPs. Trends Biochem Sci. 2021. doi:10.1016/j.tibs.2021.07.002
   PubMed Web of Science ®Google Scholar
• Zhu H, Tang YD, Zhan G, Su C, Zheng C. The critical role of PARPs in regulating innate immune responses. Front Immunol. 2021;12:712556. doi:10.3389/fimmu.2021.712556
   PubMed Web of Science ®Google Scholar
• Bohio AA, Sattout A. c-Abl-mediated tyrosine phosphorylation of PARP1 is crucial for expression of proinflammatory genes. J Immunol. 2019;203(6):1521–1531. doi:10.4049/jimmunol.1801616
   PubMed Web of Science ®Google Scholar
• Kong Q, Li Y, Liang Q, Xie J, Li X. SIRT6-PARP1 is involved in HMGB1 polyADP-ribosylation and acetylation and promotes chemotherapy-induced autophagy in leukemia. Cancer Biol Ther. 2020;21(4):320–331. doi:10.1080/15384047.2019.1702397
   PubMed Web of Science ®Google Scholar
• El-Hamoly T, Hegedűs C, Lakatos P, et al. Activation of poly(ADP-ribose) polymerase-1 delays wound healing by regulating keratinocyte migration and production of inflammatory mediators. Mol Med. 2014;20(1):363–371. doi:10.2119/molmed.2014.00130
   PubMed Web of Science ®Google Scholar
• Kiss B, Szántó M, Hegedűs C, et al. Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis. Exp Dermatol. 2020;29(1):79–85. doi:10.1111/exd.14061
   PubMed Web of Science ®Google Scholar
• Angiolilli C, Marut W, van der Kroef M, Chouri E, Reedquist KA, Radstake TRDJ. New insights into the genetics and epigenetics of systemic sclerosis. Nat Rev Rheumatol. 2018;14(11):657–673. doi:10.1038/s41584-018-0099-0
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pötter S, Chen CW, et al. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis. 2018;77(5):744–751. doi:10.1136/annrheumdis-2017-212265
   PubMed Web of Science ®Google Scholar
• Kupczyk P, Simiczyjew A, Marczuk J, et al. PARP1 as a marker of an aggressive clinical phenotype in cutaneous melanoma—a clinical and an in vitro study. Cells. 2021;10(2):286. doi:10.3390/cells10020286
   PubMed Web of Science ®Google Scholar
• Donizy P, Wu C-L, Mull J, et al. Up-regulation of PARP1 expression significantly correlated with poor survival in mucosal melanomas. Cells. 2020;9(5):1135. doi:10.3390/cells9051135
   PubMed Web of Science ®Google Scholar
• Fratangelo F, Camerlingo R, Carriero MV, et al. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. Int J Oncol. 2018;53(3):1149–1159. doi:10.3892/ijo.2018.4457
   PubMed Web of Science ®Google Scholar
• Amiri KI, Ha HC, Smulson ME, Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene. 2006;25(59):7714–7722. doi:10.1038/sj.onc.1209751
   PubMed Web of Science ®Google Scholar
• Choi J, Xu M, Makowski MM, et al. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. Nat Genet. 2017;49(9):1326–1335. doi:10.1038/ng.3927
   PubMed Web of Science ®Google Scholar
• Rodríguez MI, Peralta-Leal A, O’Valle F, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013;9(6):e1003531. doi:10.1371/journal.pgen.1003531
   PubMed Web of Science ®Google Scholar
• Cau L, Méchin MC, Simon M. Peptidylarginine deiminases and deiminated proteins at the epidermal barrier. Exp Dermatol. 2018;27(8):852–858. doi:10.1111/exd.13684
   PubMed Web of Science ®Google Scholar
• Witalison EE, Thompson PR, Hofseth LJ. Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation. Curr Drug Targets. 2015;16(7):700–710. doi:10.2174/1389450116666150202160954
   PubMed Web of Science ®Google Scholar
• Méchin M-C, Takahara H, Simon M. Deimination and peptidylarginine deiminases in skin physiology and diseases. Int J Mol Sci. 2020;21(2):566. doi:10.3390/ijms21020566
   PubMed Web of Science ®Google Scholar
• Neeli I, Radic M. Opposition between PKC isoforms regulates histone deimination and neutrophil extracellular chromatin release. Front Immunol. 2013;4:38. doi:10.3389/fimmu.2013.00038
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169(2):266–282. doi:10.1111/bjd.12355
   PubMed Web of Science ®Google Scholar
• Shelef MA, Sokolove J, Lahey LJ, et al. Peptidylarginine deiminase 4 contributes to tumor necrosis factor α-induced inflammatory arthritis. Arthritis Rheumatol. 2014;66(6):1482–1491. doi:10.1002/art.38393
   PubMed Web of Science ®Google Scholar
• Mastronardi FG, Wood DD, Mei J, et al. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J Neurosci. 2006;26(44):11387–11396. doi:10.1523/JNEUROSCI.3349-06.2006
   PubMed Web of Science ®Google Scholar
• Méchin M-C, Cau L, Galliano M-F, et al. Acefylline activates filaggrin deimination by peptidylarginine deiminases in the upper epidermis. J Dermatol Sci. 2016;81(2):101–106. doi:10.1016/j.jdermsci.2015.11.006
   PubMed Web of Science ®Google Scholar
• Ishida-Yamamoto A, Takahashi H, Iizuka H, Senshu T, Akiyama K, Nomura K. Decreased deiminated keratin K1 in psoriatic hyperproliferative epidermis. J Investig Dermatol. 2000;114(4):701–705. doi:10.1046/j.1523-1747.2000.00936.x
   PubMed Web of Science ®Google Scholar
• Curran AM, Naik P, Giles JT, Darrah E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol. 2020;16(6):301–315. doi:10.1038/s41584-020-0409-1
   PubMed Web of Science ®Google Scholar
• Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer. 2009;9:40. doi:10.1186/1471-2407-9-40
   PubMed Web of Science ®Google Scholar
• Acharya NK, Nagele EP, Han M, et al. Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease. J Autoimmun. 2012;38(4):369–380. doi:10.1016/j.jaut.2012.03.004
   PubMed Web of Science ®Google Scholar
• Ü Basmanav FB, Cau L, Tafazzoli A, et al. Mutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome. Am J Hum Genet. 2016;99(6):1292–1304. doi:10.1016/j.ajhg.2016.10.004
   PubMed Web of Science ®Google Scholar
• Odqvist L, Jevnikar Z, Riise R, et al. Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(10):1363–1370. doi:10.1136/annrheumdis-2019-215434
   PubMed Web of Science ®Google Scholar
• Lande R, Palazzo R, Hammel P, et al. Generation of monoclonal antibodies specific for native LL37 and citrullinated LL37 that discriminate the two LL37 forms in the skin and circulation of cutaneous/systemic lupus erythematosus and rheumatoid arthritis patients. Antibodies. 2020;9(2):14. doi:10.3390/antib9020014
   Web of Science ®Google Scholar
• Tang L, Chen X, Zhang X, et al. N-glycosylation in progression of skin cancer. Med Oncol. 2019;36(6):50. doi:10.1007/s12032-019-1270-4
   PubMed Web of Science ®Google Scholar
• Ząbczyńska M, Link-Lenczowski P, Pocheć E. Glycosylation in autoimmune diseases. Adv Exp Med Biol. 2021;1325:205–218. doi:10.1007/978-3-030-70115-4_10
   PubMed Web of Science ®Google Scholar
• Kelel M, Yang R-B, Tsai T-F, et al. FUT8 remodeling of EGFR regulates epidermal keratinocyte proliferation during psoriasis development. J Investig Dermatol. 2021;141(3):512–522. doi:10.1016/j.jid.2020.07.030
   PubMed Web of Science ®Google Scholar
• Zou C, Huang C, Yan L, et al. Serum N-glycan profiling as a diagnostic biomarker for the identification and assessment of psoriasis. J Clin Lab Anal. 2021;35:e23711. doi:10.1002/jcla.23711
   PubMed Web of Science ®Google Scholar
• Kirwan A, Utratna M, O’Dwyer ME, Joshi L, Kilcoyne M. Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. Biomed Res Int. 2015;2015:490531. doi:10.1155/2015/490531
   PubMed Web of Science ®Google Scholar
• Agrawal P, Fontanals-Cirera B, Sokolova E, et al. A systems biology approach identifies FUT8 as a driver of melanoma metastasis. Cancer Cell. 2017;31(6):804–819.e7. doi:10.1016/j.ccell.2017.05.007
   PubMed Web of Science ®Google Scholar
• Hu H, Li Z, Zhou Y, et al. GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma. Melanoma Res. 2019;29(6):612–620. doi:10.1097/cmr.0000000000000631
   PubMed Web of Science ®Google Scholar
• Kinslechner K, Schörghofer D, Schütz B, et al. Malignant phenotypes in metastatic melanoma are governed by SR-BI and its association with glycosylation and STAT5 activation. Mol Cancer Res. 2018;16(1):135–146. doi:10.1158/1541-7786.MCR-17-0292
   PubMed Web of Science ®Google Scholar
• de Queiroz RM, Oliveira IA, Piva B, et al. Hexosamine biosynthetic pathway and glycosylation regulate cell migration in melanoma cells. Front Oncol. 2019;9:116. doi:10.3389/fonc.2019.00116
   PubMed Web of Science ®Google Scholar
• Yang L, Guo W, Zhang S, Wang G. Ubiquitination-proteasome system: a new player in the pathogenesis of psoriasis and clinical implications. J Dermatol Sci. 2018;89(3):219–225. doi:10.1016/j.jdermsci.2017.12.002
   PubMed Web of Science ®Google Scholar
• Ganesan AK, Kho Y, Kim SC, Chen Y, Zhao Y, White MA. Broad spectrum identification of SUMO substrates in melanoma cells. Proteomics. 2007;7(13):2216–2221. doi:10.1002/pmic.200600971
   PubMed Web of Science ®Google Scholar
• Lakhter AJ, Kanginakudru S, Warren S, Touloukian CE, Boissy RE, Naidu SR. Impaired PIASy-Tip60 signaling weakens activation of p53 in melanoma. Melanoma Res. 2013;23(3):213–217. doi:10.1097/CMR.0b013e328361056d
   PubMed Web of Science ®Google Scholar
• Shim HS, Wei M, Brandhorst S, Longo VD. Starvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells. Cancer Res. 2015;75(6):1056–1067. doi:10.1158/0008-5472.can-14-2249
   PubMed Web of Science ®Google Scholar
• Zhou M, Lin F, Xu W, Jin R, Xu A. Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep. 2018;18(3):3469–3475. doi:10.3892/mmr.2018.9299
   PubMed Web of Science ®Google Scholar
• Ge H, Li B, Chen W, et al. Differential occurrence of lysine 2-hydroxyisobutyrylation in psoriasis skin lesions. J Proteomics. 2019;205:103420. doi:10.1016/j.jprot.2019.103420
   PubMed Web of Science ®Google Scholar
• Zhou B, Yang W, Li W, et al. Zdhhc2 is essential for plasmacytoid dendritic cells mediated inflammatory response in psoriasis. Front Immunol. 2020;11:607442. doi:10.3389/fimmu.2020.607442
   PubMed Web of Science ®Google Scholar
• Sun LN, Zhi Z, Chen LY, et al. SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p. Cancer Lett. 2017;409:104–115. doi:10.1016/j.canlet.2017.09.001
   PubMed Web of Science ®Google Scholar
• Wang Y, Huo J, Zhang D. Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-κB signaling. J Cell Biochem. 2019;120(4):6459–6470. doi:10.1002/jcb.27936
   PubMed Web of Science ®Google Scholar
• Krueger JG, Suárez-Fariñas M, Cueto I, et al. A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. PLoS One. 2015;10(11):e0142081. doi:10.1371/journal.pone.0142081
   PubMed Web of Science ®Google Scholar
• Sun T, Jiao L, Wang Y, Yu Y, Ming L. SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells. Cell Death Dis. 2018;9(2):136. doi:10.1038/s41419-017-0167-4
   PubMed Web of Science ®Google Scholar
• Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13(5):454–463. doi:10.1016/j.ccr.2008.03.004
   PubMed Web of Science ®Google Scholar
• Wilking MJ, Singh CK, Nihal M, Ndiaye MA, Ahmad N. Sirtuin deacetylases: a new target for melanoma management. Cell Cycle. 2014;13(18):2821–2826. doi:10.4161/15384101.2014.949085
   PubMed Web of Science ®Google Scholar
• Rizvi A, Merlin MA, Shah GM. Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: potential impact in cancer stem cells and therapeutic implications. Eur J Pharmacol. 2021;911:174546. doi:10.1016/j.ejphar.2021.174546
   PubMed Web of Science ®Google Scholar
• Djokic-Gallagher J, Rosher P, Hart V, Walker J. Steroid-sparing effects and acceptability of a new skin gel containing the anti-inflammatory medicinal substance-nicotinamide. Clin Cosmet Investig Dermatol. 2019;12:545–552. doi:10.2147/ccid.s210444
   PubMed Web of Science ®Google Scholar
• Lande R, Pietraforte I, Mennella A, et al. Complementary effects of carbamylated and citrullinated LL37 in autoimmunity and inflammation in systemic lupus erythematosus. Int J Mol Sci. 2021;22(4):1650. doi:10.3390/ijms22041650
   PubMed Web of Science ®Google Scholar
• Nagai T, Saito M, Tanoue Y, Kai N, Suzuki N. Characterization of collagen from sakhalin taimen skin as useful biomass. Food Technol Biotechnol. 2020;58(4):445–454. doi:10.17113/ftb.58.04.20.6734
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang T. Upregulated E3 ligase tripartite motif-containing protein 21 in psoriatic epidermis ubiquitylates nuclear factor-κB p65 subunit and promotes inflammation in keratinocytes. Br J Dermatol. 2021;184(1):111–122. doi:10.1111/bjd.19057
   PubMed Web of Science ®Google Scholar